Recent advances in genomics and sequencing technology have led to a better understanding of genetic risk in CKD. Genetics could account in part for racial differences in treatment response for medications including antihypertensives and immunosuppressive medications due to its correlation with ancestry. However, there is still a substantial lag between generation of this knowledge and its adoption in routine clinical care. This review summarizes the recent advances in genomics and CKD, discusses potential reasons for its underutilization, and highlights potential avenues for application of genomic information to improve clinical care and outcomes in this particularly vulnerable population.

Original languageEnglish
Pages (from-to)120-124
Number of pages5
JournalAdvances in Chronic Kidney Disease
Issue number2
StatePublished - 1 Mar 2016


  • CKD
  • Disparities
  • Genetics
  • Genomics
  • Pharmacogenomics


Dive into the research topics of 'Genomics in CKD: Is This the Path Forward?'. Together they form a unique fingerprint.

Cite this